NASDAQ:RNAC Cartesian Therapeutics Q2 2026 Earnings Report $7.94 -0.09 (-1.12%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Cartesian Therapeutics EPS ResultsActual EPS$0.46Consensus EPS -$0.88Beat/MissBeat by +$1.34One Year Ago EPSN/ACartesian Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.18 millionBeat/MissN/AYoY Revenue GrowthN/ACartesian Therapeutics Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsCartesian Therapeutics' next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules. Conference Call ResourcesSEC FilingEarnings HistoryCompany Profile Cartesian Therapeutics Earnings HeadlinesCartesian Therapeutics Announces New Employment Inducement GrantsSeptember 8, 2026 | globenewswire.comCartesian Therapeutics to Participate in Upcoming Investor ConferencesSeptember 3, 2026 | globenewswire.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 21 at 1:00 AM | Chaikin Analytics (Ad)Cantor Fitzgerald Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)August 9, 2026 | theglobeandmail.comCartesian Therapeutics Announces New Employment Inducement GrantsAugust 7, 2026 | globenewswire.comCartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 6, 2026 | markets.businessinsider.comSee More Cartesian Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cartesian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cartesian Therapeutics and other key companies, straight to your email. Email Address About Cartesian TherapeuticsCartesian Therapeutics (NASDAQ:RNAC) (NASDAQ: RNAC) is a clinical-stage biotechnology company developing cell therapies for autoimmune diseases. Its research focuses on mRNA cell therapy, an approach designed to program a patient’s own immune cells to target disease-related proteins while enabling transient expression of the therapeutic construct. The company’s lead program, Descartes-08, is an autologous anti-BCMA CAR T-cell therapy that uses mRNA to direct T cells against B-cell maturation antigen. Cartesian has been evaluating Descartes-08 in autoimmune conditions, including generalized myasthenia gravis, and is also advancing additional programs based on its mRNA CAR T-cell platform. Cartesian is headquartered in Gaithersburg, Maryland, and conducts research and clinical development activities primarily in the United States. The company became publicly traded following a 2023 business combination with Selecta Biosciences. Carsten Brunn serves as Cartesian’s president and chief executive officer.View Cartesian Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep WinningJ.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to Growth Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
